Roche has shuttered a heart transplant trial combining its immunosuppressant drug CellCept with sirolimus--an immunosuppressant sold by Wyeth as Rapamune--after seeing an unexpectedly high rate of organ rejection. Patients were switched from a combination of calcineurin inhibitor and CellCept. Report